

Sedation Consortium on Endpoints and Procedures for Treatment, Education, and Research (SCEPTER-III)

Clinical Trials to Evaluate Patient-Centered Outcomes of Sedation in Mechanically Ventilated Patients in the Adult ICU

Westin Georgetown Hotel - Washington, DC

MEETING AGENDA

Thursday, March 28, 2019						
7:30 – 8:00 ам	Continental Breakfast	Washington Ballroom				
8:00 – 8:30 AM	Welcome and Introductions	Bob Dworkin,				
8:30 – 8:45 AM	Procedural Sedation – SCEPTER 1 & 2	Denham Ward				
	Goals for SCEPTER 3					
8:45 – 10:00 ам	Panel Discussion: Current Clinical Guidelines	Douglas Coursin (moderator)				
	SCCM PADIS guidelines: Pain, Agitation/Sedation,	John Devlin, Yoanna Skrobik				
	Delirium, Immobility and Sleep Impairment					
10:00 – 10:30 ам	Break					
10:30 – 11:00 ам	Patient and family perspective	David Brown				
11:00 – 11:30 ам	Establishing core outcome measures and instruments: A	Dale Needham				
	case study in evaluating post-discharge status of ICU					
	survivors					
11:30 – 12:00 РМ	Q&A and Panel Discussion: How to incorporate the	Pam Flood (moderator)				
	patient's and families' perspective	David Brown, Dale Needham,				
		Ingrid Egerod				
12:00 – 1:00 РМ	Lunch	Mayfair Court				
1:00 – 1:30 рм	SEDCOM, MENDS, MIDEX & PRODEX – Lessons	Richard Riker				
	learned for study design, outcomes and measures					
1:30 - 2:00 рм	Evaluating efficacy in ICU sedation clinical trials: a	Martha Van Clief				
	regulatory perspective					
2:00 - 2:30 рм	Q&A and Panel Discussion: Current controversies, and	Gil Fraser, Douglas Coursin				
	unmet needs	(moderators)				
		Yoanna Skrobik, Mervyn Maze,				
		Richard Riker, Martha Van Clief				
2:30 -3:00 РМ	Break					
3:00 - 3:30 рм	Design issues for clinical trials of ICU sedation	Daniel Sessler				
3:30 - 4:00 рм	Clinical Trials for new ICU Sedation Protocols	Leanne Aitken				
4:00 - 4:30 РМ	Statistical issues in clinical trial design for ICU sedation	Elizabeth Colantuoni				
4:30 – 5:00 PM	Q&A and Panel Discussion: Clinical trial design	Steve Shafer(moderator),				
		Daniel Sessler, Leanne Aitken,				
		Franklin Dexter, Elizabeth				
		Colantuoni, Yahya Shehabi				
7:00 – 9:00 PM	Dinner	Mayfair Court				

Friday, March 29, 2019							
7:30 – 8:00 AM	Continental Breakfast	Washington Ballroom					
8:00 – 8:30 AM	Defining and measuring light vs moderate sedation / analgesia	Pratik Pandharipande					
8:30 – 9:00 AM	Case Study: Approval of Dexmed for ICU sedation	Mervyn Maze					
9:00 – 10:00 am	Panel Discussion: Who should be studied and how? Patient inclusion / exclusion criteria Sedation / analgesia prior to enrollment "Rescue" medications Controls (placebo vs active vs usual) Multicenter vs single center Informed consent Enrollment size; allocation ratio; stopping rule Adaptive trial design; interim analysis Primary vs secondary end points; composite outcomes Subgroup enrollment and analysis Planned statistical analysis; properties of proposed measurement instruments Phase 2, Phase 3, seamless Phase 2/3, Phase 4 study designs	Avery Tung (moderator)					
10:00 – 10:30 ам	Break						
10:30 – 12:00 РМ	Panel Discussion: Evaluating acute use of ICU sedation/analgesia • Sedation level measure and frequency of measurement - RASS, Ramsay sedation scale, Sedation-Agitation Scale, Glasgow Coma Scale, BIS, etc. • Pain assessment and frequency of measurement – Behavioral pain scale, CPOT, NVPS, VAS, Faces, FLACC, COMFORT other? • Delirium measurement (CAM-ICU, ICDSC, other?), frequency of measurement and treatment, interaction with sedation level • Use of "wake-up" • Efficacy outcomes • % time within RASS target • Use of rescue medications • Days alive without delirium or coma • Sleep states (polysomnography) • Safety outcomes (during sedation) • Mortality • Unplanned extubations during sedation • Length of sedation / mechanical ventilation • Over-sedation (coma) criteria	Yoanna Skrobik (moderator)					
12:00 – 1:00 РМ	Lunch	Mayfair Court					
1:00 – 2:30 РМ	Panel Discussion: Acute, Subacute and chronic outcomes after ICU sedation Mortality - ICU, Post ICU (how long after ICU D/C?) ICU days and Hospital days Cognitive function and memory measurement (IQCODE, MMSE, Trials-B, etc.) and frequency (28, 180 days, 1 year?) Physical functioning (6MWT, other?) HRQOL (EQ-5D, SF-36v2, ADL, other?)	Tim Girard (moderator)					
0.00 0.00	Pain and PTSD (CAPS, long term opioid use, other?) CAPS III CAPS III						
2:30 – 3:00 РМ	Group Discussion: SCEPTER-III next steps	Denham Ward					